A Combination of Pegfilgrastim and Filgrastim has No Benefit compared to Filgrastim alone for autologous Stem Cell

作者: Irmgard Bumeder , Fuat S. Oduncu , Ralf Schmidmaier , S Fuat

DOI:

关键词:

摘要: Background: Autologous stem cell transplantation is an established therapy for various hematological malignancies. A precondition the efficient and save mobilization of blood cells, which achieved by treatment with granulocytecolony stimulating factors. Previously, it has been demonstrated that pegylated form filgrastim, pegfilgrastim, comparable to filgrastim in efficiency mobilization. Here, we examine, whether a combination pegfilgrastim exerts benefit compared alone safety autologous Patients methods: We retrospectively analyzed data 131 patients undergoing transplantation. The received (n = 66) or 65)

参考文章(20)
Bing-Bing Yang, Anna Kido, Pharmacokinetics and Pharmacodynamics of Pegfilgrastim Clinical Pharmacokinetics. ,vol. 50, pp. 295- 306 ,(2011) , 10.2165/11586040-000000000-00000
Ingmar Bruns, Ulrich Steidl, Ralf Kronenwett, Roland Fenk, Thorsten Graef, Ulrich-Peter Rohr, Frank Neumann, Johannes Fischer, Christof Scheid, Kai Hübel, Rainer Haas, Guido Kobbe, A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma Transfusion. ,vol. 46, pp. 180- 185 ,(2006) , 10.1111/J.1537-2995.2006.00699.X
Simona Bassi, Cristina Rabascio, Luca Nassi, Sara Steffanoni, Aleksandra Babic, Paola Bertazzoni, Federica Gigli, Pierluigi Antoniotti, Laura Orlando, Simona Sammassimo, Jessica Quarna, Mara Negri, Giovanni Martinelli, A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy Transfusion and Apheresis Science. ,vol. 43, pp. 321- 326 ,(2010) , 10.1016/J.TRANSCI.2010.10.001
Amanda Cashen, Sandra Lopez, Feng Gao, Gary Calandra, Ron MacFarland, Karin Badel, John DiPersio, A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma Biology of Blood and Marrow Transplantation. ,vol. 14, pp. 1253- 1261 ,(2008) , 10.1016/J.BBMT.2008.08.011
Lorin K. Roskos, Peggy Lum, Pamela Lockbaum, Gisela Schwab, Bing-Bing Yang, Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. The Journal of Clinical Pharmacology. ,vol. 46, pp. 747- 757 ,(2006) , 10.1177/0091270006288731
I. Bruns, U. Steidl, J. C. Fischer, A. Czibere, G. Kobbe, S. Raschke, R. Singh, R. Fenk, M. Rosskopf, S. Pechtel, A. von Haeseler, P. Wernet, D. G. Tenen, R. Haas, R. Kronenwett, Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica. ,vol. 93, pp. 347- 355 ,(2008) , 10.3324/HAEMATOL.12081
S Fruehauf, J Klaus, J Huesing, M R Veldwijk, E C Buss, J Topaly, T Seeger, L W J Zeller, T Moehler, A D Ho, H Goldschmidt, Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation. ,vol. 39, pp. 743- 750 ,(2007) , 10.1038/SJ.BMT.1705675